<p>Fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) are the clinical gold standards for screening blood sugar levels, yet they provide only static snapshots that fail to reflect the highly dynamic and heterogeneous nature of metabolic impairment. However, continuous glucose monitoring (CGM) is r</p>